Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaFRA:IP40 -3.91%58 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates FRA:IP40 with a GF Score™ of 58/100 and a GF Value™ of €7.08 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,952 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 51229.46% on this metric.
InnoCan Pharma's average Accounts Receivable for the
three
months ended in Jun. 2026 was €0.00 Mil. InnoCan Pharma's Revenue for the
three
months ended in Jun. 2026 was €4.56 Mil.
Hence, InnoCan Pharma's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 0.00.
The historical rank and industry rank for InnoCan Pharma's Days Sales Outstanding or its related term are showing as below:
During the past 8 years, InnoCan Pharma's highest Days Sales Outstanding was 109.50. The lowest was 0.20. And the median was 2.10.
FRA:IP40's Days Sales Outstanding is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 38.63 * Ranked among companies with meaningful Days Sales Outstanding only.
InnoCan Pharma's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
InnoCan Pharma (FRA:IP40) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
InnoCan Pharma Days Sales Outstanding Related Terms
InnoCan Pharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:IP40 vs PG, CL, EL: Days Sales Outstanding Comparison
For the Household & Personal Products subindustry, InnoCan Pharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Days Sales Outstanding vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (FRA:IP40) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on InnoCan Pharma and its competitors. Over the past decade, InnoCan Pharma's Days Sales Outstanding has ranged from 0.20 to 109.50. According to the industry distribution chart, InnoCan Pharma ranks #999999 out of 1952 companies in the Consumer Packaged Goods industry.
Is InnoCan Pharma's Days Sales Outstanding too high?
InnoCan Pharma's current Days Sales Outstanding is 0.00. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 109.50. Based on the distribution chart, InnoCan Pharma ranks #999999 out of 1952 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Days Sales Outstanding compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #999999 out of 1952 companies for Days Sales Outstanding. This places InnoCan Pharma in the lower half of its industry. The industry median Days Sales Outstanding is 38.63. Historically, InnoCan Pharma's own Days Sales Outstanding has ranged from 0.20 to 109.50 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Consumer Packaged Goods company?
The median Days Sales Outstanding among Consumer Packaged Goods companies is 38.63, based on 1,952 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Days Sales Outstanding is 38.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (FRA:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €7.08, compared to a current price of €1.23 — trading 82.6% below its estimated fair value. The current Days Sales Outstanding is 0.00. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For InnoCan Pharma (FRA:IP40), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (FRA:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.23 is trading 82.6% below its estimated GF Value™ of €7.08.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for FRA:IP40:
Days Sales Outstanding: 0.00
GF Value™: €7.08 vs. price of €1.23 (82.6% below fair value)
No single metric tells the full story. See the FRA:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for FRA:IP40
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IP40 has been successfully added to your 
